Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming  

作　　者：Roos S G Sablerolles 

机构地区：[1]不详

出　　处：《四川生理科学杂志》2021年第11期1861-1861,共1页Sichuan Journal of Physiological Sciences

摘　　要：Background:The Ad26.COV2.S vaccine,which was approved as a single-shot immunization regimen,has been shown to be effective against severe coronavirus disease 2019.However,this vaccine induces lower severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)spike protein(S)-specific antibody levels than those induced by messenger RNA(mRNA)-based vaccines.The immunogenicity and reactogenicity of a homologous or heterologous booster in persons who have received an Ad26.COV2.S priming dose are unclear.

关 键 词：VACCINE acute RESPIRATORY 

分 类 号：R37[医药卫生—病原生物学]